Charles Redfern

Title(s)Associate Physician, Family Medicine and Public Health
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    G PROTEIN SIGNALING AND TISSUE PROLIFERATION
    NIH/NCI K08CA071779Jul 5, 1996 - Jun 30, 2001
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer. 2022 01; 163:19-26. Plummer R, Dean E, Arkenau HT, Redfern C, Spira AI, Melear JM, Chung KY, Ferrer-Playan J, Goddemeier T, Locatelli G, Dong J, Fleuranceau-Morel P, Diaz-Padilla I, Shapiro GI. PMID: 34894455.
      View in: PubMed   Mentions:
    2. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. J Immunother Cancer. 2020 09; 8(2). Verschraegen CF, Jerusalem G, McClay EF, Iannotti N, Redfern CH, Bennouna J, Chen FL, Kelly K, Mehnert J, Morris JC, Taylor M, Spigel D, Wang D, Grote HJ, Zhou D, Munshi N, Bajars M, Gulley JL. PMID: 32907924; PMCID: PMC7481079.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    3. Reply to T.J.A. Dekker. J Clin Oncol. 2020 10 01; 38(28):3351-3352. Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. PMID: 32658630.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov. 2020 05; 10(5):688-701. Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, Saito K, Sugihara M, Singh J, Jikoh T, Gallant G, Li BT. PMID: 32213540; PMCID: PMC8292921.
      View in: PubMed   Mentions: 30     Fields:    
    5. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol. 2020 06 10; 38(17):1887-1896. Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. PMID: 32058843; PMCID: PMC7280051.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    6. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019 06; 20(6):816-826. Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S. PMID: 31047803.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    7. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018 07; 19(7):975-986. Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F. PMID: 29880291.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    8. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Sep 01; 21(17):3862-9. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND. PMID: 25925891.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    9. Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors. Anticancer Drugs. 2015 Apr; 26(4):448-55. Eppler S, Gordon MS, Redfern CH, Trudeau C, Xu N, Han K, Lum BL. PMID: 25643049.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    10. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1251-60. Xu N, Redfern CH, Gordon M, Eppler S, Lum BL, Trudeau C. PMID: 25344761; PMCID: PMC4236615.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    11. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol. 2011 Aug; 68(2):547-52. Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD. PMID: 21516509.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    12. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29; 363(5):411-22. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators. PMID: 20818862.
      View in: PubMed   Mentions: 1779     Fields:    Translation:HumansCellsCTClinical Trials
    13. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother. 2010 Feb-Mar; 33(2):178-84. Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF. PMID: 20145546.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    14. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007 Feb 20; 25(6):669-74. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW, ASCENT Investigators. PMID: 17308271.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    15. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 01; 24(19):3089-94. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. PMID: 16809734.
      View in: PubMed   Mentions: 351     Fields:    Translation:HumansCTClinical Trials
    16. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol. 2006 Jul 01; 24(19):3107-12. Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF. PMID: 16754937.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCellsCTClinical Trials
    17. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother. 2004 May-Jun; 27(3):232-9. Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD. PMID: 15076141.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsCTClinical Trials
    18. Tools for dissecting signaling pathways in vivo: receptors activated solely by synthetic ligands. Methods Enzymol. 2002; 343:232-48. Scearce-Levie K, Coward P, Redfern CH, Conklin BR. PMID: 11665570.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    Charles's Networks
    Concepts (119)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (4)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version v3.1.0-871-g21b54b14 on PROFILES-PWEB01.

    Copyright © The Regents of the University of California